|   | ***Certain                confidential information contained in this document, marked by brackets,                has been omitted and filed with the Securities and Exchange Commission                pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as                amended.** |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Amendment      No. 1**

**PHS**
**TGC**
**First Amendment**

**License Agreement**
**Licensed Products**
**IAVI**
**Licensee**

**License Agreement**
**License Agreement**

**License Agreement**

| 1. | The                Recitations on the Cover Page of the “**Agreement**”                are amended to add a Reference to Appendix G - Royalty Payment                Options which is also being added by this **First Amendment**                The amended text of the recitations reads as                follows: |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Agreement**
**Agreement**
**Agreement**

|   | 1) | The                National Institutes of Health (“NIH”), the Centers for Disease Control and                Prevention (“CDC”), or the Food and Drug Administration (“FDA”),                hereinafter singly or collectively referred to as “**PHS”**,                agencies of the United States Public Health Service within the                Department of Health and Human Services (“**DHHS”**);                and |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2) | The                person, corporation, or institution identified above and/or on the                Signature Page, having offices at the address indicated on the                Signature Page, and its **Affiliates**                as                defined in Appendix D, Paragraph 2.14, hereinafter referred                to as “**Licensee**”. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2. | Appendix C,                Section C **Earned Royalties**                is                amended to read as follows: |
|----|---------------------------------------------------------------------------------------------------------------------------------------|

|   | C. | **Earned Royalty(ies)**                pursuant to Paragraph 6.03, as amended and set forth in                Appendix D, of this **Agreement**: |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Licensee**
**PHS**
**Agreement**
**Earned Royalty**
**Net Sales**

|   | 1. | **[*]**                Percent (**[*]**%)                of **Net Sales**                of                **Licensee**                and its sublicensees of all **Licensed Products**                manufactured and sold in the **Licensed Territory**. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Licensee**
**[*]**
**[*]**
**Licensee**
**Licensed Products**
**Licensed Products**
**[*]**

**Earned      Royalty(ies)**
**PHS**
**Licensed Products**
**Developing World**
**Developing World**
**Licensee**
**IAVI**
**Licensee**
**Licensed Products**
**IAVI**
**Developing World**
**TGC**
**PHS**
**Licensee**
**PHS**

**Licensed Product**
**Developing World**

**First      Amendment Continues on Next Page**

***Confidential      Treatment      Requested.**

----

| 3. | Appendix C,                Section D shall be amended to read as                follows. |
|----|----------------------------------------------------------------------------------------------------|

|   | **D.** | **Benchmark Royalty(ies)**                pursuant to Paragraph 6.04, as amended and set forth in                Appendix D, of this **Agreement**: |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Licensee**
**PHS**
**Benchmark Royalties**

| **Benchmark**                                                                                                                                                                                                                                                | **Benchmark Royalty** |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| For                each **[*]**                up                to a total of **[*]**,                at the time of **[*]**                of                a **[*]**                or                equivalent clinical trial for a particular **[*]** | **[*]**                    |
| For                each **[*]**,                up to a total of **[*]**,                at the time of **[*]**                of                a **[*]**                or                equivalent clinical trial for a particular **[*]**               | **[*]**                    |
| For                each **[*]**,                up to a total of **[*]**,                at the time of **[*]**                for a particular **[*]**                                                                                                      | **[*]**                    |

**Benchmark Royalty**
**PHS**
**Licensee**
**Person**
**Agreement**
**Licensee**
**Benchmark**
**PHS**
**Licensee**
**Benchmark Royalty**
**PHS**
**Licensee**
**Licensee**

**Benchmark Royalty(ies)**
**PHS**
**Agreement**
**Benchmark**
**Licensed Product**
**Developing World**
**Licensee**
**IAVI**

**Licensed Product**
**Benchmark Royalties**

| 4. | Appendix                D - Modifications is amended to add the following Paragraph 2.18 to                Article 2 - Definitions: |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.18. | “**Developing World**”                means those countries defined from time to time by the World Bank                as                having “low-income economies” or “middle-income economies” (whether                lower-middle or upper-middle). |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

***Confidential        Treatment        Requested.**

----

| 5. | Appendix                D - Modifications is changed to amend Paragraph 9.06 to reflect that                Appendix G has been added to the **Agreement**.                Paragraph 9.06 as amended reads as                follows: |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.06 | Royalties                due under Article 6 shall be paid in U.S. dollars and payment                options are listed in Appendix G. For conversion of foreign currency                to U.S. dollars, the conversion rate shall be the average New York                foreign exchange rate quoted in *The                Wall Street Journal*                for the previous thirty (30) trading days prior to the date the                payment is due. All checks and bank drafts shall be drawn on                United States banks and shall be payable, as appropriate, to                “NIH/Patent Licensing”. Any loss of exchange, value, taxes, or other                expenses incurred in the transfer or conversion to U.S. dollars shall                be paid entirely by **Licensee**.                The royalty report required by Paragraph 9.04 of this **Agreement**                shall accompany each such payment, and a copy of such report shall                also be                mailed to **PHS**                at                its address for Agreement Notices indicated on the Signature Page of                this **First Amendment**. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**First      Amendment Continues on Next Page**

----

| 6. | Appendix G                - Royalty Payment Information is added to the **Agreement**                in                order to facilitate the administration of the **Agreement**                in                the future. New Appendix G reads as                follows: |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**APPENDIX      G - ROYALTY PAYMENT OPTIONS**

***NIH/PHS      License Agreements***

****In      order to process payment via Electronic Funds Transfer sender MUST supply the      following information***
*:*

***Procedure      for Transfer of Electronic Funds to NIH for Royalty      Payments***

**[*]**

**[*]**

***Mailing      Address for Royalty Payments:***

***Overnight      Mail for Royalty Payments only***

*      NIH/Patent Licensing*

*The      OTT Reference Number *
***MUST***
*appear      on checks, reports and correspondence*

***Confidential        Treatment        Requested.**

----

| 6. | This                **First Amendment**                is                effective on the date on which the last party executes this **First Amendment**. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7. | Unless                expressly modified by this **First Amendment**                the terms and conditions of the **License Agreement**                are incorporated in their entirety into the terms and conditions                of this                **First Amendment**                and this **First Amendment**                together with the **License Agreement**                constitute the entire agreement between the parties and all prior                negotiations, representations, agreements, and understandings are                merged                into, extinguished by, and completely expressed by this **First Amendment**. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**SIGNATURES      BEGIN ON NEXT PAGE**

----

**SIGNATURE      PAGE**

**For      PHS:**

| /s/              Steven M. Ferguson                                                                                                                                                                                                                                                                   |   | 8/14/06  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|
| Steven                M. Ferguson, MBA Director,                Division of Technology Development and TransferOffice                of Technology TransferNational                Institutes of Health                                                                                               |   | Date          |
|                                                                                                                                                                                                                                                                                                       |   |          |
| Mailing                Address for Agreement Notices:Chief,                Monitoring and Enforcement BranchOffice                of Technology TransferNational                Institutes of Health6011                Executive Boulevard, Suite 325Rockville,                Maryland 20852-3804 U.S.A. |   |          |

**Licensee      **
**Licensee**

**Licensee**

| /s/                B.G. Susan Robinson        |   | 08-18-06  |
|---------------------------------------------------------|--------|----------------|
| Signature                  of Authorized Official  |   | Date           |
|                                                    |   |           |
| B.G.                  Susan Robinson               |   |           |
| Printed Name                                            |   |           |
|                                                    |   |           |
| VP,                Business Development            |   |           |
| Title                                                   |   |           |

| I. | Official                and Mailing Address for Agreement                Notices: |
|----|-----------------------------------------------------------------------------------|

----

| II. | Official                and Mailing Address for Financial Notices (**Licensee’s**                contact person for royalty                payments) |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Susan                Robinson                        |   |
|--------|-----------------------------------------------------------|--------|
|   | Name                                                      |   |
|   |                                                      |   |
|   | Vice                President, Business Development  |   |
|   | Title                                                     |   |
|   |                                                      |   |
|   | Mailing Address:                                          |   |
|   |                                                      |   |
|   | 1100                  Olive Way, Suite 100                |   |
|   |                                                      |   |
|   | Seattle,                  WA 98101                   |   |
|   |                                                      |   |
|   |                                                      |   |
|   |                                                      |   |
|   |                                                      |   |

| Email                Address:  | susan.robinson@targen.com  |   |
|-------------------------------------|---------------------------------|--------|
|                                |                            |   |
| Phone:                         | 206-521-7330               |   |
|                                |                            |   |
| Fax:                      | 206-512-4782                    |   |

**Government**
**Agreement**
**Agreement**

----